SRRK
What one share of Scholar Rock Holding holds
Biological Products, (No Diagnostic Substances)
We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (“SMA”) and additional rare, severe and debilitating neuromuscular diseases.
Scholar Rock Holding’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$3.32 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.41 |
| Cash and investments | $4.05 |
| Debt | $1.61 |
| Book value | $2.09 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$15.30 | $0.22 | −$13.52 | — | — |
| 2018 | $0.00 | −$3.15 | $0.10 | $1.47 | — | $4.07 |
| 2019 | $0.74 | −$1.85 | $0.11 | −$2.40 | — | $3.79 |
| 2020 | $0.50 | −$2.81 | $0.13 | −$2.09 | — | $7.64 |
| 2021 | $0.51 | −$3.59 | $0.14 | −$3.60 | — | $4.89 |
| 2022 | $0.56 | −$2.26 | $0.02 | −$2.24 | — | $5.04 |
| 2023 | — | −$1.99 | $0.00 | −$1.74 | — | $2.96 |
| 2024 | — | −$2.47 | $0.00 | −$2.01 | — | $3.93 |
| 2025 | $0.00 | −$3.29 | $0.01 | −$2.62 | — | $2.26 |